CDMO launched to service increasing demand for exosomes 

Stem cells

EXO Biologics has launched ExoXpert, a contract development and manufacturing organisation (CDMO) specialising in exosomes which offers a mesenchymal stem cells (MSC)-based exosome manufacturing platform used in European clinical trials. 

During the development of its lead exosome candidate, EXOB-001, Exo Biologics developed ExoPulse, an industrial exosome manufacturing platform designed for GMP production of exosomes. In July 2023 the European Medicines Agency (EMA) authorised the EVENEW study, a Phase I/II European clinical trial using EXOB-001. This is EXO Biologics’ lead MSC-based exosome candidate for prevention of Bronchopulmonary Dysplasia (BPD) in preterm newborns. 

“The potential of exosomes continues to be demonstrated across the cell and gene therapy sector. As a result, exosome-based clinical trials have the potential to significantly increase in number, if industrial supply of exosomes can be met. Currently there is a lack of exosome production, manufacturing specialists and facilities to supply exosomes for both R&D and clinical trials,” said Romain de Rauville, Chief Business Officer, EXO Biologics. “ExoXpert has been launched using our expertise in the development of exosome-based therapeutics to offer GMP-compliant specialist exosome manufacturing capabilities to the market. This will make a significant contribution to the industry’s efforts to develop exosome-based products.” 

“Challenges around producing and characterising exosomes remain a significant barrier to the development of exosome-based therapeutics and their delivery to patients. In addition, navigating the regulatory pathways to their production is a major hinderance across the market,” said Hugues Wallemacq, CEO, EXO Biologics. “EXO Biologics has now developed a regulatory-compliant GMP manufacturing platform and facility that provides a solution to biotech companies developing exosome-based therapeutics. ExoXpert is already supporting the development of products for two biotech companies and is at the center of ExoFasttrack, a major Biowin project, to create an industrial exosome ecosystem. EXO Biologics has launched ExoXpert to be a major division of the company with the aim of contributing to the global development of exosomes.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free